In 2010, Ariad announced final result from a period I analyze of ponatinib in clients with resistant and refractory Persistent myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Disclaimer: Healthline has built each and every energy to help make particular that eac